The 8th Biennial Meeting of the Asian Society of Gynecologic Oncology, December 1st to 3rd, 2023

Heng-Cheng Hsu,김재원,박정열,서동훈,김세익,Jen-Ruei Chen,Peng-Hui Wang 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.2

As per the 2018 GLOBOCAN database, Asia accounted for 48.7% (637,761) of new gynecologiccancer cases and 50.1% (305,000) of gynecologic cancer deaths [1]. Recognizing the distinctdifferences in genetic background, cancer epidemiology, disease characteristics, and socio-cultural environment between Asian and non-Asian women, it is noteworthy that much ofthe experimental evidence guiding clinical gynecologic oncology practices has historicallybeen drawn from studies in Western populations. Established in 2008, the Asian Society ofGynecologic Oncology (ASGO) ser ves as a key organization in Asia, dedicated to advancingthe study, prevention, and treatment of gynecological cancer through scientific exchange,regional/international collaboration, educational initiatives, and fostering camaraderieamong its members [2]. Presently, ASGO boasts members from over 10 countries in Asia. Building on the success of the previous meetings held in Tokyo (2009) [3], Seoul (2011)[4], Kyoto (2013) [5], Seoul (2015) [6], Tokyo (2017) [7], Incheon (2019) [8], and Bangkok(2021) [9], the eighth Biennial Meeting of ASGO took place at the state-of-the-art HNBKInternational Convention Center in Taipei, Taiwan, from December 01 to 03, 2023. Theoverarching theme for this event was “Reunion to Overcome Gynecologic Cancer in Asia.”Notably, due to the impact of the coronavirus disease 2019 pandemic in 2021, the meetingwas transformed into a hybrid format. This gathering marked a significant milestone as thefirst in-person Pan-Asia meeting focused on gynecological cancer following the pandemic. Additionally, it is worth highlighting that this was the inaugural ASGO meeting held outsideof Korea and Japan, underscoring the broadening geographical scope and global impactof the conference. Professor Peng-Hui Wang and Jae-Weon Jim chaired the organizingcommittee. ASGO 2023 witnessed the participation of 633 attendees from 17 countries,featuring 152 honored speakers and chairs from 12 countries. The event included 44 oral/surgical video presentations and 187 poster presentations, covering a diverse range ofscientific topics, from fundamental principles of gynecological cancer care to advanced, high-technology practices rooted in cutting-edge research (Table 1). Photos from the meetingare accessible on the official meeting website (http://tinyurl.com/26xtts2f ).

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

( Chen-hua Liu ),( Chi-yi Chen ),( Wei-wen Su ),( Chun-jen Liu ),( Ching-chu Lo ),( Ke-jhang Huang ),( Jyh-jou Chen ),( Kuo-chih Tseng ),( Chi-yang Chang ),( Cheng-yuan Peng ),( Yu-lueng Shih ),( Chia 대한간학회 2021 Clinical and Molecular Hepatology(대한간학회지) Vol.27 No.4

Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR₁₂) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. The safety profiles were reported. Results: The SVR₁₂ rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI], 82.5-94.2%), 94.1% (95% CI, 87.8-97.3%), and 100% (95% CI, 96.2-100%). Number of patients who failed to achieve SVR₁₂ were attributed to virologic failures. The SVR₁₂ rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR₁₂, 84.4% and 64.6% had improved Child-Pugh and model for endstage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score ≥15 was associated with an improved MELD score of ≥3 (odds ratio, 4.13; 95% CI, 1.16-14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 ㎡/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 ㎡/month; P<0.001). Conclusions: SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis. (Clin Mol Hepatol 2021;27:575-588)

Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study

An Jen Chiang,Min-Yu Chen,Chia-Sui Weng,Hao Lin,Chien-Hsing Lu,Peng-Hui Wang,Yu-Fang Huang,Ying-Cheng Chiang,Mu-Hsien Yu,Chih-Long Chang 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.5

Objective: The malignant transformation (MT) of ovarian mature cystic teratoma (MCT)to squamous cell carcinoma (SCC) is very rare. This study analyzed cases from multiplemedical centers in Taiwan to investigate the clinicopathologic characteristics, treatment, andprognostic factors of this disease and reviewed related literature. Methods: Pathological reports of 16,001 patients with primary ovarian cancer who weretreated at Taiwan medical centers from 1990 to 2011 were reviewed. In total, 52 patients withMT of MCT to SCC were identified. Results: Among all ovarian MCTs, the incidence of MT to SCC is 0.2%. The median age ofpatients was 52 years (range, 29–89 years), and the mean tumor size was 10.5 cm (range, 1–40cm). We analyzed the patients in our study and those in the literature and determined thatearly identification and complete surgical resection of the tumor are essential for long-termsurvival. In addition, adjuvant chemotherapy or concurrent chemoradiotherapy can be usedto treat this malignancy. Old age, large tumor size (≥15.0 cm), and solid components in MCTsare suitable indicators predicting the risk of MT of MCT to SCC. Conclusion: Similar to general epithelial ovarian cancers, the early detection of MT of MCTto SCC is critical to long-term survival. Therefore, older patients with a large tumor or those with a tumor containing a solid component in a clinically diagnosed MCT should beevaluated to exclude potential MT to SCC.

Predatory efficacy of Orius strigicollis (Hemiptera: Anthocoridae) against Tetranychus urticae (Acarina: Tetranychidae) on strawberry

Shu-Jen Tuan,Yung-Hsiang Lin,Shu-Chen Peng,Wei-Han Lai 한국응용곤충학회 2016 Journal of Asia-Pacific Entomology Vol.19 No.1

In this study, the predatory efficacy of Orius strigicollis (Poppius), a predacious flower bug, against the twospotted spider mite (TSSM), Tetranychus urticae Koch, on strawberry (Fragaria ananassa) was investigated. Our results showed that release of 2, 4, 6, and 12 neonates of O. strigicollis per strawberry plant could suppress 58.9, 72.6, 88.6, and 92.8% of T. urticae, respectively, at 14 days after treatment. A single release of 12 neonate bugs per plant achieved and maintained, over a period of 3 months, 82% to 98% control of T. urticae population. A biweekly release of 6 neonate bugs per plant; likewise, suppressed ca. 90% of T. urticae population throughout the same period. However, predatory efficacy was reduced by an over-release of predators which may cause cannibalism as well as lower possibility of finding prey. Since the released neonates survived well to adults with offspring that retained their predatory ability, this study has demonstrated that O. strigicollis is a predatorwith good potential for sustainable suppression of T. urticae on strawberry, and one application of O. strigicollis neonates at a predator:prey ratio of 1:200 egg plus motile TSSM or 1:60 motiles per strawberry plant promises a season-long control and substantial management of spider mite infestation.

A False Positive 18F-FDG PET/CT Scan Caused by Breast Silicone Injection

Chao-Jung Chen,Bi-Fang Lee,Wei-Jen Yao,Pei-Shan Wu,Wen-Chung Chen,Shu-Lin Peng,Nan-Tsing Chiu 대한영상의학회 2009 Korean Journal of Radiology Vol.10 No.2

We present here the case of a 40-year-old woman with a greater than 10 year prior history of bilateral breast silicone injection and saline bag implantation. Bilateral palpable breast nodules were observed, but the ultrasound scan was suboptimal and the magnetic resonance imaging showed no gadoliniumenhanced tumor. The 18F-FDG PET/CT scan showed a hypermetabolic nodule in the left breast with a 30% increase of 18F-FDG uptake on the delayed imaging, and this mimicked breast cancer. She underwent a left partial mastectomy and the pathology demonstrated a siliconoma.

Superconducting topological surface states in non-centrosymmetric bulk superconductor PbTaSe₂

Syu-You Guan,Peng-Jen Chen,Ming-Wen Chu,Raman Sankar,Fangcheng Chou,Horng-Tay Jeng,Tien-Ming Chuang,Chia-Seng Chang 한국진공학회 2016 한국진공학회 학술발표회초록집 Vol.2016 No.8

The development of Taiwan Fracture Liaison Service network

Lo-Yu Chang,Keh-Sung Tsai,Jen-Kuei Peng,Chung-Hwan Chen,Gau-Tyan Lin,Chin-Hsueh Lin,Shih-Te Tu,I-Chieh Mao,Yih-Lan Gau,Hsusan-Chih Liu,Chi-Chien Niu,Min-Hong Hsieh,Jui-Teng Chien,Wei-Chieh Hung,Rong-S 대한골다공증학회 2018 Osteoporosis and Sarcopenia Vol.4 No.2

Osteoporosis and its associated fragility fractures are becoming a severe burden in the healthcare system globally. In the Asian-Pacific (AP) region, the rapidly increasing in aging population is the main reason accounting for the burden. Moreover, the paucity of quality care for osteoporosis continues to be an ongoing challenge. The Fracture Liaison Service (FLS) is a program promoted by International Osteoporosis Foundation (IOF) with a goal to improve quality of postfracture care and prevention of secondary fractures. In this review article, we would like to introduce the Taiwan FLS network. The first 2 programs were initiated in 2014 at the National Taiwan University Hospital and its affiliated Bei-Hu branch. Since then, the Taiwan FLS program has continued to grow exponentially. Through FLS workshops promoted by the Taiwanese Osteoporosis Association (TOA), program mentors have been able to share their valuable knowledge and clinical experience in order to promote establishments of additional programs. With 22 FLS sites including 11 successfully accredited on the best practice map, Taiwan remains as one of the highest FLS coverage countries in the AP region, and was also granted the IOF Best Secondary Fracture Prevention Promotion award in 2017. Despite challenges faced by the TOA, we strive to promote more FLS sites in Taiwan with a main goal of ameliorating further health burden in managing osteoporotic patients.

Core prescription pattern of Chinese herbal medicine for depressive disorders in Taiwan: a nationwide population-based study

Diem Ngoc Hong Tran,I-Hsuan Hwang,Fun-Jou Chen,Yuan-Pu Tseng,Ching-Mao Chang,Shih-Jen Tsai,Jen-Lin Yang,Ta-Peng Wu,Chung-Hua Hsu,Fang-Pey Chen,Yen-Ying Kung 한국한의학연구원 2021 Integrative Medicine Research Vol.10 No.3

Background: Depressive disorders (DD) affect not only mood and behavior but also various physical functions. Traditional Chinese medicine (TCM) has been shown to have some benefits in treating DD. However, one formula or one single herb might be not show high efficacy when used to treat depression. Thus, this study aimed to examine the core prescription pattern of Chinese herbal medicine (CHM) among patients with DD in Taiwan as a reference for related research and clinical applications. Methods: All patients, who had been diagnosed with major depressive disorder or minor depression or dysthymia without any other baseline diseases and had at least one CHM outpatient clinical visit from 2002 to 2011, were extracted from three randomly sampled cohorts, namely the 2000, 2005 and 2010 cohorts of the National Health Insurance Research Database (NHIRD) of Taiwan. The collected data was analyzed to explore the patterns of herbal products. Results: There were 197,146 patients with a diagnosis of DD and of these 1806 subjects had only a diagnosis of DD and utilized CHM. The most common formula was Gan-Mai-Da-Zao-Tang (12.19%), while Suan-Zao-Ren (3.99%) was the most commonly prescribed single herb. The core pattern of prescriptions consisted of a combination of Gan-Mai-Da-Zao-Tang, Jia-Wei-Xiao-Yao-San, Chai-Hu-Jia-Long-Gu-Mu-Li-Tang, He-Huan-Pi, Yuan-Zhi and Shi-Chang-Pu. Conclusions: This study describes the CHM core prescription pattern used to treat patients in Taiwan with DD and it is a potential candidate for study in future pharmacological or clinical trials targeting DD.